Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Response-adapted treatment in CLL

Carsten Niemann • 13 Dec 2021
ASH 2021
Chronic Lymphocytic Leukemia Leukemia

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, highlights the need for find the optimal duration of treatment in patients with chronic lymphocytic leukemia (CLL). Personalized treatments with durations based on patient needs, existing comorbidities, or disease factors can change how quickly patients can respond to treatment. Minimal residual disease (MRD) testing is therefore, important for personalized medicine by assessing when individual patients should cease treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Carsten Niemann

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
3:20
Explainable machine learning to identify CLL-driven changes on the gut microbiome
Carsten Niemann • 6 Oct 2023
3:27
The implementation of a data-driven CLL-TIM algorithm into an EPIC-based electronic health record
Carsten Niemann • 6 Oct 2023
2:25
Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial
Carsten Niemann • 6 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals